Tralokinumab联合外用糖皮质激素治疗中重度特应性皮炎:III期ECZTRA 3试验结果
ECZTRA 3是一项双盲、随机、多中心、安慰剂对照III期试验,评估Tralokinumab联合按需外用糖皮质激素(TCS)治疗中重度特应性皮炎(AD)的疗效与安全性。Tralokinumab 300 mg联合TCS有效且耐受性良好。
要点
- Tralokinumab联合TCS显著提高第16周IGA 0/1和EASI 75应答率。
- 第16周应答者继续治疗至第32周,Q2W和Q4W方案均能维持较高应答率。
- Tralokinumab 300 mg联合TCS总体不良事件发生率与安慰剂组相似。
核心结论
- Tralokinumab 300 mg联合按需TCS治疗中重度AD有效且耐受性良好。
研究设计与样本
- 双盲、随机、多中心、安慰剂联合TCS对照的III期试验。
- 患者按2:1随机接受皮下Tralokinumab 300 mg或安慰剂每2周一次,联合按需TCS,治疗16周。
- 第16周达到IGA 0/1和/或EASI 75的Tralokinumab组患者按1:1再随机接受Tralokinumab每2周或每4周一次,联合按需TCS,继续治疗16周。
主要发现
- 总体不良事件发生率在各治疗组间相似。
临床怎么用
- 对于中重度AD且适合系统治疗的患者,可考虑Tralokinumab 300 mg每2周一次联合按需TCS。
- 第16周应答者可继续Tralokinumab治疗,每2周或每4周一次联合TCS维持疗效。
- 第16周未达标者继续Tralokinumab Q2W治疗至第32周仍可能获得IGA 0/1或EASI 75应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate-to-severe AD who were candidates for systemic therapy. METHODS: This was a double-blind, placebo plus TCS controlled phase III trial. Patients were randomized 2 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) with TCS as needed over 16 weeks. Patients who achieved an Investigator's Global Assessment (IGA) score of 0/1 and/or 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab were rerandomized 1 : 1 to tralokinumab Q2W or every 4 weeks (Q4W), with TCS as needed, for another 16 weeks. RESULTS: At week 16, more patients treated with tralokinumab than with placebo achieved IGA 0/1: 38·9% vs. 26·2% [difference (95% confidence interval): 12·4% (2·9-21·9); P = 0·015] and EASI 75: 56·0% vs. 35·7% [20·2% (9·8-30·6); P < 0·001]. Of the patients who were tralokinumab responders at week 16, 89·6% and 92·5% of those treated with tralokinumab Q2W and 77·6% and 90·8% treated with tralokinumab Q4W maintained an IGA 0/1 and EASI 75 response at week 32, respectively. Among patients who did not achieve IGA 0/1 and EASI 75 with tralokinumab Q2W at 16 weeks, 30·5% and 55·8% achieved these endpoints, respectively, at week 32. The overall incidence of adverse events was similar across treatment groups. CONCLUSIONS: Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.
引用
- Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021. PMID: 33000503. doi:10.1111/bjd.19573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。